232 filings
Page 3 of 12
8-K
wt1h96t l6j5fy2iaz2s
27 Jul 22
Other Events
7:30am
8-K
vfkx1jt6
22 Jul 22
Entry into a Material Definitive Agreement
4:20pm
8-K
p37kn17 pn0zu8h
28 Jun 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
4:13pm
8-K
lh736zmap54a1z zt
23 May 22
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
5:42pm
8-K
jp0w50pe5vd4h2juv
16 May 22
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
12:00am
8-K
0wpm8gvn
4 May 22
Other Events
4:33pm
8-K
pvvk hxiw7
18 Apr 22
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan
4:25pm
8-K
66rldfw
12 Apr 22
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
9:08am
8-K
8cr5ipq
8 Apr 22
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders
5:04pm
8-K
jj8v7k5l749qgpczv
21 Mar 22
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
4:26pm
8-K
ppy3nffa
18 Mar 22
Entry into a Material Definitive Agreement
5:14pm
8-K
phvml0izkg68qfh6
21 Dec 21
Other Events
4:06pm
8-K
i3c x97vh6c
24 Nov 21
Other Events
4:15pm
8-K
k4j3 5209w418mc
10 Nov 21
Diffusion Pharmaceuticals Reports Third Quarter Financial Results
8:01am
8-K
4a5t8tp
5 Nov 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:43pm
8-K
mzmf8lit
12 Oct 21
Regulation FD Disclosure
7:04am
8-K
fq3y5k4xce fjtd09at
13 Sep 21
Diffusion Pharmaceuticals Issues Letter to Shareholders
4:09pm
8-K
82ksk24bgsyf9
13 Aug 21
Diffusion Pharmaceuticals Reports Q2 Financial Results
4:30pm
8-K
2jcv9q4t2nb334tg
30 Jun 21
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
4:33pm
8-K
wuch4f0
29 Jun 21
Submission of Matters to a Vote of Security Holders
9:05am